Physician profile
Catherine Cunningham
NPI 1982009486
$2,106.31
in general payments reported to CMS, 2019-2025
22 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.86 · 2022: $675 · 2023: $687 · 2024: $296 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $425.99 | 2022-2025 | Caplyta |
| Abbvie INC. | $301.45 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $202.82 | 2022-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $172.42 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Corium, LLC | $141.90 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $131.43 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $119.96 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $107.20 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $73.51 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $72.88 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $71.14 | 2022-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $53.14 | 2022 | |
| Avanir Pharmaceuticals, INC. | $42.61 | 2022 | |
| Sage Therapeutics, LLC | $35.14 | 2024-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $31.04 | 2024 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $22.49 | 2025 | Kisunla, Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $20.99 | 2025 | Trintellix |
| Harmony Biosciences LLC | $19.80 | 2024 | |
| Indivior INC. | $16.53 | 2023 | Perseris |
| Tempus Ai, INC | $15.97 | 2024 | |
| Neuronetics, INC. | $14.86 | 2023 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.